NLS Pharmaceutics AG NLSP shares are trading lower by 40% to $0.30 Thursday morning after the company announced it is seeking strategic alternatives to enhance shareholder value by exploring partnerships, licensing its intellectual property and implementing cost-saving measures.
NLS Pharmaceutics says the company has initiated steps like partnering to license their key asset, securing additional financing and reducing their workforce by 50%. The moves aim to diversify revenue, extend cash reserves and streamline operations while maintaining a commitment to innovation and quality.
The company's CEO invites stakeholders to follow their journey as they navigate these changes, expressing confidence that these initiatives will strengthen their position as a leader in therapies for complex nervous system disorders.
See Also: Why Is Cancer Firm Apollomics Stock Trading Higher Today?
According to data from Benzinga Pro, NLSP has a 52-week high of $1.88 and a 52-week low of $0.30.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
